CA2783797C - Mass spectrometric determination of non-derivatized, non-metabolized vitamin d - Google Patents
Mass spectrometric determination of non-derivatized, non-metabolized vitamin d Download PDFInfo
- Publication number
- CA2783797C CA2783797C CA2783797A CA2783797A CA2783797C CA 2783797 C CA2783797 C CA 2783797C CA 2783797 A CA2783797 A CA 2783797A CA 2783797 A CA2783797 A CA 2783797A CA 2783797 C CA2783797 C CA 2783797C
- Authority
- CA
- Canada
- Prior art keywords
- vitamin
- ions
- sample
- column
- metabolized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940046008 vitamin d Drugs 0.000 title abstract description 98
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 191
- 238000000034 method Methods 0.000 claims abstract description 152
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 66
- 150000002500 ions Chemical class 0.000 claims description 306
- 239000000523 sample Substances 0.000 claims description 129
- 239000011647 vitamin D3 Substances 0.000 claims description 113
- 239000011653 vitamin D2 Substances 0.000 claims description 110
- 229940021056 vitamin d3 Drugs 0.000 claims description 110
- 229960002061 ergocalciferol Drugs 0.000 claims description 109
- 239000002243 precursor Substances 0.000 claims description 109
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 99
- 235000005282 vitamin D3 Nutrition 0.000 claims description 98
- 235000001892 vitamin D2 Nutrition 0.000 claims description 95
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 94
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 93
- 229940088594 vitamin Drugs 0.000 claims description 80
- 239000011782 vitamin Substances 0.000 claims description 80
- 229930003231 vitamin Natural products 0.000 claims description 53
- 235000013343 vitamin Nutrition 0.000 claims description 53
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 53
- 238000000605 extraction Methods 0.000 claims description 42
- 238000004811 liquid chromatography Methods 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 32
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 32
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 31
- 210000002966 serum Anatomy 0.000 claims description 27
- -1 vitamin D2 ions Chemical class 0.000 claims description 21
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 claims description 20
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 18
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 17
- 239000012472 biological sample Substances 0.000 claims description 11
- 239000011710 vitamin D Substances 0.000 abstract description 97
- 229930003316 Vitamin D Natural products 0.000 abstract description 96
- 235000019166 vitamin D Nutrition 0.000 abstract description 96
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract description 92
- 238000001514 detection method Methods 0.000 abstract description 22
- 239000012491 analyte Substances 0.000 description 73
- 239000000047 product Substances 0.000 description 59
- 238000001228 spectrum Methods 0.000 description 45
- 238000013467 fragmentation Methods 0.000 description 36
- 238000006062 fragmentation reaction Methods 0.000 description 36
- 238000003556 assay Methods 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 32
- 239000012071 phase Substances 0.000 description 26
- ISULLEUFOQSBGY-UHFFFAOYSA-N 4-phenyl-1,2,4-triazole-3,5-dione Chemical compound O=C1N=NC(=O)N1C1=CC=CC=C1 ISULLEUFOQSBGY-UHFFFAOYSA-N 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 241000950629 Icteria Species 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- 206010018910 Haemolysis Diseases 0.000 description 15
- 238000004587 chromatography analysis Methods 0.000 description 15
- 239000007789 gas Substances 0.000 description 15
- 230000008588 hemolysis Effects 0.000 description 15
- 239000002207 metabolite Substances 0.000 description 15
- 230000007704 transition Effects 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000002245 particle Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000006920 protein precipitation Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- 238000001212 derivatisation Methods 0.000 description 10
- 230000000717 retained effect Effects 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000003795 desorption Methods 0.000 description 8
- 238000000132 electrospray ionisation Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 238000002540 product ion scan Methods 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000000622 liquid--liquid extraction Methods 0.000 description 6
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000000638 solvent extraction Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- 150000001793 charged compounds Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 235000021318 Calcifediol Nutrition 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001360 collision-induced dissociation Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 229940028435 intralipid Drugs 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012421 spiking Methods 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- NPKSULYVSICWLD-UHFFFAOYSA-N 4-[2-(6,7-dimethoxy-4-methyl-3-oxoquinoxalin-2-yl)ethyl]-1,2,4-triazole-3,5-dione Chemical compound O=C1N(C)C=2C=C(OC)C(OC)=CC=2N=C1CCN1C(=O)N=NC1=O NPKSULYVSICWLD-UHFFFAOYSA-N 0.000 description 3
- JSACPXBJRYHNHN-UHFFFAOYSA-N 4-[4-(6-methoxy-1,3-benzoxazol-2-yl)phenyl]-1,2,4-triazole-3,5-dione Chemical compound O1C2=CC(OC)=CC=C2N=C1C(C=C1)=CC=C1N1C(=O)N=NC1=O JSACPXBJRYHNHN-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010265 fast atom bombardment Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000009616 inductively coupled plasma Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000005040 ion trap Methods 0.000 description 3
- 230000001000 lipidemic effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000012521 purified sample Substances 0.000 description 3
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 238000002553 single reaction monitoring Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 2
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 2
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 2
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229960004361 calcifediol Drugs 0.000 description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
- 229960005084 calcitriol Drugs 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000451 chemical ionisation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 239000007792 gaseous phase Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 238000009428 plumbing Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000002098 selective ion monitoring Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- CXVOIIMJZFREMM-UHFFFAOYSA-N 1-(2-nitrophenoxy)octane Chemical compound CCCCCCCCOC1=CC=CC=C1[N+]([O-])=O CXVOIIMJZFREMM-UHFFFAOYSA-N 0.000 description 1
- BPKAHTKRCLCHEA-FOPGHSPUSA-N 19-Nor-1-α,25-dihydroxyvitamin D2 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C=C[C@H](C)C(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-FOPGHSPUSA-N 0.000 description 1
- 239000003872 25-hydroxy-cholecalciferol Substances 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- XRYKNRLGZZNWEE-UHFFFAOYSA-N 4-methyl-1,2,4-triazole-3,5-dione Chemical compound CN1C(=O)N=NC1=O XRYKNRLGZZNWEE-UHFFFAOYSA-N 0.000 description 1
- UOELMDIOCSFSEN-FVZZCGLESA-N 7-Dehydrositosterol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)C=C[C@H](C)C(C)C)=CC=C1C[C@@H](O)CCC1=C.C1[C@@H](O)CCC2(C)C(CC[C@@]3([C@@H]([C@H](C)C=C[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 UOELMDIOCSFSEN-FVZZCGLESA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241001123248 Arma Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 208000022458 calcium metabolism disease Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- PKOQLWGZTUJUPG-UHFFFAOYSA-N cyclopenta-1,3-diene;4-(cyclopenta-2,4-dien-1-ylmethyl)-1,2,4-triazole-3,5-dione;iron(2+) Chemical compound [Fe+2].C=1C=C[CH-]C=1.O=C1N=NC(=O)N1C[C-]1C=CC=C1 PKOQLWGZTUJUPG-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960000465 dihydrotachysterol Drugs 0.000 description 1
- ILYCWAKSDCYMBB-OPCMSESCSA-N dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940075049 dovonex Drugs 0.000 description 1
- 229940083272 drisdol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000004750 isotope dilution mass spectroscopy Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000447 pesticide residue Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940052212 zemplar Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/004—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/10—Ion sources; Ion guns
- H01J49/14—Ion sources; Ion guns using particle bombardment, e.g. ionisation chambers
- H01J49/145—Ion sources; Ion guns using particle bombardment, e.g. ionisation chambers using chemical ionisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N2030/009—Extraction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Plasma & Fusion (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28593809P | 2009-12-11 | 2009-12-11 | |
| US28594309P | 2009-12-11 | 2009-12-11 | |
| US61/285,943 | 2009-12-11 | ||
| US61/285,938 | 2009-12-11 | ||
| PCT/US2010/059765 WO2011072163A1 (en) | 2009-12-11 | 2010-12-09 | Mass spectrometric determination of non-derivatized, non-metabolized vitamin d |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2783797A1 CA2783797A1 (en) | 2011-06-16 |
| CA2783797C true CA2783797C (en) | 2021-06-08 |
Family
ID=44145925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2783797A Active CA2783797C (en) | 2009-12-11 | 2010-12-09 | Mass spectrometric determination of non-derivatized, non-metabolized vitamin d |
Country Status (6)
| Country | Link |
|---|---|
| US (8) | US20120025067A1 (enExample) |
| EP (1) | EP2510339B1 (enExample) |
| JP (3) | JP6113504B2 (enExample) |
| CN (1) | CN102753964A (enExample) |
| CA (1) | CA2783797C (enExample) |
| WO (2) | WO2011072163A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745226B2 (en) | 2005-04-06 | 2010-06-29 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites |
| US7972868B2 (en) | 2007-11-28 | 2011-07-05 | Quest Diagnostics Investments Incorporated | Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry |
| US7977117B2 (en) | 2009-12-03 | 2011-07-12 | Quest Diagnostics Investments Incorprated | Vitamin D metabolite determination utilizing mass spectrometry following derivatization |
| CA2783797C (en) | 2009-12-11 | 2021-06-08 | Quest Diagnostics Investments Incorporated | Mass spectrometric determination of non-derivatized, non-metabolized vitamin d |
| CA2783708C (en) | 2009-12-11 | 2018-09-18 | Quest Diagnostics Investments Incorporated | Mass spectrometry of steroidal compounds in multiplex samples |
| CA2787900C (en) * | 2010-01-25 | 2018-10-02 | Dh Technologies Development Pte. Ltd. | Quantitative analysis of vitamin d3, vitamin d2, and metabolites thereof |
| WO2014149847A2 (en) | 2013-03-15 | 2014-09-25 | Riaz Abrar | Ionization within ion trap using photoionization and electron ionization |
| CN108027353A (zh) * | 2015-03-28 | 2018-05-11 | 帝肯样品制备股份有限公司 | 固相萃取、用冠醚衍生化、以及质谱、方法、试剂和试剂盒 |
| CN105403631B (zh) * | 2015-10-28 | 2017-12-08 | 浙江省疾病预防控制中心 | 一种快速检测保健食品中维生素d3含量的方法 |
| WO2018198043A1 (en) * | 2017-04-28 | 2018-11-01 | Waters Technologies Corporation | Methods for quantifying total vitamin d |
| US20210088486A1 (en) * | 2018-01-29 | 2021-03-25 | Dh Technologies Development Pte. Ltd. | Methods and systems for detection of vitamin d metabolites |
| CN111999372A (zh) * | 2020-07-09 | 2020-11-27 | 山东师范大学 | 可高通量筛选喹喔啉衍生物合成条件的微液滴电喷雾装置及方法 |
| WO2023155000A1 (en) * | 2022-02-15 | 2023-08-24 | Mcmaster University | High throughput rapid screening of vitamin d |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3030084A (en) | 1958-11-06 | 1962-04-17 | Tillotson Mfg Co | Charge forming apparatus |
| US4332591A (en) * | 1978-01-19 | 1982-06-01 | Sumitomo Chemical Company, Limited | Analytical method and apparatus for the determination of total nitrogen contents in aqueous systems |
| US5030772A (en) | 1990-02-14 | 1991-07-09 | Deluca Hector F | Process for preparing vitamin D2 compounds and the corresponding 1 α-hydroxylated derivatives |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| JPH06341980A (ja) | 1993-02-24 | 1994-12-13 | Kureha Chem Ind Co Ltd | ビタミンｄ３誘導体の定量法 |
| EP0700521B1 (en) | 1993-05-28 | 2003-06-04 | Baylor College Of Medicine | Method and mass spectrometer for desorption and ionization of analytes |
| JP2968910B2 (ja) | 1993-07-14 | 1999-11-02 | ヤマサ醤油株式会社 | １α，２５（ＯＨ）２ビタミンＤ３に対する抗体及びその用途 |
| WO1995033279A1 (en) | 1994-05-31 | 1995-12-07 | University Of Warwick | Tandem mass spectrometry apparatus |
| DE19531152A1 (de) | 1994-12-15 | 1996-06-20 | Bayer Ag | Substituierte N-Aryl-Stickstoffheterocyclen |
| US5614408A (en) * | 1995-10-18 | 1997-03-25 | The United States Of America As Represented By The Secretary Of Agricultural | Monoclonal antibodies to potato, tomato, and eggplant glycoalkaloids and assays for the same |
| US5772874A (en) | 1995-11-02 | 1998-06-30 | Cohesive Technologies, Inc. | High performance liquid chromatography method and apparatus |
| ES2140209T3 (es) | 1996-01-19 | 2000-02-16 | Cohesive Tech Inc | Procedimiento y dispositivo de cromatografia de liquidos de alto rendimiento. |
| CA2270132A1 (en) | 1996-11-06 | 1998-05-14 | Sequenom, Inc. | Dna diagnostics based on mass spectrometry |
| US5916523A (en) * | 1996-12-04 | 1999-06-29 | Antek Instruments, Inc. | Methods for near simultaneous chemiluminescent sulfur and nitrogen detection |
| WO1998051663A2 (en) * | 1997-05-16 | 1998-11-19 | F. Hoffmann-La Roche Ag | 3-epi compounds of vitamin d3 and uses thereof |
| GB9717926D0 (en) | 1997-08-22 | 1997-10-29 | Micromass Ltd | Methods and apparatus for tandem mass spectrometry |
| GB9719187D0 (en) | 1997-09-09 | 1997-11-12 | Glaxo Group Ltd | Compounds |
| AU2463299A (en) | 1998-01-23 | 1999-08-09 | Analytica Of Branford, Inc. | Mass spectrometry from surfaces |
| EP1097132B1 (de) | 1998-06-25 | 2003-12-17 | Immundiagnostik Gesellschaft für Produktion und Vertrieb von Labordiagnostika mbH | Funktionelle vitamin-d-derivate und verfahren zur bestimmung von 25-hydroxy- und 1alpha,25-dihydroxy-vitamin-d |
| WO2001040177A2 (en) | 1999-12-02 | 2001-06-07 | Women And Infants Hospital | Esters of vitamin d3 and uses thereof |
| GB0029729D0 (en) | 2000-12-06 | 2001-01-17 | Ids Ltd | Method for detection of vitamin D metabolites |
| US7087395B1 (en) | 2001-01-16 | 2006-08-08 | Quest Diagnostics Investments Incorporated | Vitamin D assay |
| WO2003046148A2 (en) | 2001-11-29 | 2003-06-05 | Thermo Finnigan Llc | Polypeptide quantitation |
| TWI286554B (en) * | 2002-06-27 | 2007-09-11 | Chugai Pharmaceutical Co Ltd | Ferrocene compounds and uses thereof |
| US7632686B2 (en) | 2002-10-03 | 2009-12-15 | Anderson Forschung Group | High sensitivity quantitation of peptides by mass spectrometry |
| CA2501000C (en) | 2002-10-03 | 2015-05-26 | Norman Leigh Anderson | High sensitivity quantitation of peptides by mass spectrometry |
| US7473560B2 (en) * | 2003-04-14 | 2009-01-06 | Georgetown University | Steroid hormone analysis by mass spectrometry |
| CA2519626C (en) | 2003-04-14 | 2013-06-18 | Georgetown University | Thyroid hormone analysis by mass spectrometry with minimal sample preparation |
| US6977143B1 (en) | 2003-09-08 | 2005-12-20 | Quest Diagnostics Investments Incorporated | Determination of testosterone by mass spectrometry |
| WO2005050226A1 (en) | 2003-11-14 | 2005-06-02 | Irm Llc | Fluorous labeling for selective processing of biologically-derived samples |
| JP4555994B2 (ja) | 2003-12-19 | 2010-10-06 | 日立化成工業株式会社 | バックライト装置及び液晶表示装置 |
| WO2005117906A1 (en) | 2004-05-19 | 2005-12-15 | Merck & Co., Inc. | Combination for inhibiting bone resorption comprising a bisphosponate (alendrona) and a vitamin d (cholecalciferol) |
| CA2480549A1 (fr) | 2004-09-15 | 2006-03-15 | Phytronix Technologies Inc. | Source d'ionisation pour spectrometre de masse |
| US20060094039A1 (en) | 2004-09-20 | 2006-05-04 | Ron Rosenfeld | Diagnosis of fetal aneuploidy |
| US7700365B2 (en) | 2004-10-29 | 2010-04-20 | Mayo Foundation For Medical Education And Research | Vitamin D deficiencies |
| US20070037286A1 (en) | 2005-02-09 | 2007-02-15 | Subhasish Purkayastha | Thyroxine-containing compound analysis methods |
| WO2006107339A2 (en) | 2005-03-31 | 2006-10-12 | Georgetown University | Free thyroxine and free triiodothyronine analysis by mass spectrometry |
| US7745226B2 (en) | 2005-04-06 | 2010-06-29 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites |
| US7972867B2 (en) | 2005-04-06 | 2011-07-05 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites by mass spectrometry |
| ES2498973T3 (es) | 2005-04-06 | 2014-09-26 | Washington University In St. Louis | Métodos para medir in vivo biomoléculas procedentes del sistema nervioso |
| US20060236886A1 (en) | 2005-04-20 | 2006-10-26 | Agfa-Gevaert | Process for the offset printing of a catalytic species via a hydrophilic phase |
| WO2007039193A1 (en) | 2005-09-29 | 2007-04-12 | Roche Diagnostics Gmbh | Antibodies against 25-hydroxyvitamin d |
| US20070105179A1 (en) | 2005-11-09 | 2007-05-10 | Dionex Corporation | Methods of detecting N-and O-linked oligosaccharides in glycoproteins |
| US7855057B2 (en) | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
| US7989760B2 (en) | 2006-05-24 | 2011-08-02 | SWCE Inc. | Extraction detection system and method |
| US7935921B2 (en) * | 2006-05-26 | 2011-05-03 | Laboratory Corporation Of America Holdings | Methods and systems for the quantitative analysis of biomarkers |
| DE602007003833D1 (de) | 2006-06-06 | 2010-01-28 | Roche Diagnostics Gmbh | Verbesserte vitamin-d-messung |
| US7906341B2 (en) | 2006-06-30 | 2011-03-15 | Dh Technologies Development Pte, Ltd. | Methods, mixtures, kits and compositions pertaining to analyte determination |
| EP2069054A1 (en) | 2006-08-30 | 2009-06-17 | GE Healthcare Bio-Sciences Corp. | System and method for characterizing membranes and membrane filtration devices |
| US7999084B2 (en) * | 2007-05-16 | 2011-08-16 | Agilent Technologies, Inc. | Devices and methods for reducing matrix effects |
| US7807172B2 (en) | 2007-06-13 | 2010-10-05 | University Of Washington | Methods and compositions for detecting thyroglobulin in a biological sample |
| JP4883540B2 (ja) | 2007-06-21 | 2012-02-22 | 国立大学法人福井大学 | 同位体化合物を標識として使用するタンパク質の分析方法 |
| JP5080945B2 (ja) | 2007-11-09 | 2012-11-21 | 株式会社日立ハイテクノロジーズ | 質量分析装置および質量分析方法 |
| US7972868B2 (en) | 2007-11-28 | 2011-07-05 | Quest Diagnostics Investments Incorporated | Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry |
| US8030084B2 (en) | 2007-12-06 | 2011-10-04 | Quest Diagnostics Investments Incorporated | Thyroglobulin quantitation by mass spectrometry |
| US20110212534A1 (en) | 2008-08-11 | 2011-09-01 | Taylor Robert L | Methods for determining levels of 1,25 dihydroxy vitamin d2 and d3 |
| WO2010099108A2 (en) | 2009-02-24 | 2010-09-02 | Mayo Foundation For Medical Education And Research | Multiplexing derivatized anayltes using mass spectroscopy |
| US7977117B2 (en) | 2009-12-03 | 2011-07-12 | Quest Diagnostics Investments Incorprated | Vitamin D metabolite determination utilizing mass spectrometry following derivatization |
| US8034627B2 (en) | 2009-12-03 | 2011-10-11 | Quest Diagnostics Investments Incorporated | Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry |
| CA2783708C (en) | 2009-12-11 | 2018-09-18 | Quest Diagnostics Investments Incorporated | Mass spectrometry of steroidal compounds in multiplex samples |
| CA2783797C (en) | 2009-12-11 | 2021-06-08 | Quest Diagnostics Investments Incorporated | Mass spectrometric determination of non-derivatized, non-metabolized vitamin d |
| CA2787900C (en) | 2010-01-25 | 2018-10-02 | Dh Technologies Development Pte. Ltd. | Quantitative analysis of vitamin d3, vitamin d2, and metabolites thereof |
| WO2011116028A1 (en) | 2010-03-15 | 2011-09-22 | Anderson Forschung Group, Inc. | Improved mass spectrometric assays for peptides |
| EP2633325B1 (en) | 2010-10-29 | 2016-12-28 | Cohesive Technologies Inc. | Lc-ms separation and detection of vitamin d metabolites |
| JPWO2012111249A1 (ja) | 2011-02-14 | 2014-07-03 | 学校法人麻布獣医学園 | 質量分析法における質量変化を検出する方法及び安定同位体標識タンパク質の絶対量の定量方法 |
| US9140695B2 (en) | 2012-01-18 | 2015-09-22 | University Of Utah Research Foundation | Methods for analysis of free and autoantibody-bound biomarkers and associated compositions, devices, and systems |
| WO2014047316A1 (en) | 2012-09-20 | 2014-03-27 | Quest Diagnostics Investments Incorporated | Thyroglobulin quantitation by mass spectroscopy |
| JP7209363B2 (ja) | 2020-04-13 | 2023-01-20 | リオモ インク | スタビリティ評価システム、プログラム及び方法 |
-
2010
- 2010-12-09 CA CA2783797A patent/CA2783797C/en active Active
- 2010-12-09 EP EP10836711.1A patent/EP2510339B1/en not_active Not-in-force
- 2010-12-09 CN CN2010800635404A patent/CN102753964A/zh active Pending
- 2010-12-09 WO PCT/US2010/059765 patent/WO2011072163A1/en not_active Ceased
- 2010-12-09 US US12/964,710 patent/US20120025067A1/en not_active Abandoned
- 2010-12-09 WO PCT/US2010/059771 patent/WO2011072168A1/en not_active Ceased
- 2010-12-09 US US12/964,717 patent/US20110240840A1/en not_active Abandoned
- 2010-12-09 JP JP2012543290A patent/JP6113504B2/ja active Active
-
2015
- 2015-07-31 JP JP2015152480A patent/JP6290145B2/ja active Active
-
2016
- 2016-06-27 US US15/194,009 patent/US20170115314A1/en not_active Abandoned
-
2018
- 2018-02-07 JP JP2018020278A patent/JP6728254B2/ja active Active
- 2018-08-01 US US16/051,849 patent/US10753950B2/en active Active
-
2020
- 2020-08-24 US US17/001,425 patent/US11280799B2/en active Active
-
2022
- 2022-03-21 US US17/700,320 patent/US11549954B2/en active Active
- 2022-12-30 US US18/091,726 patent/US11852636B2/en active Active
-
2023
- 2023-11-07 US US18/503,388 patent/US20240077503A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6728254B2 (ja) | 2020-07-22 |
| EP2510339B1 (en) | 2019-09-18 |
| JP2018105878A (ja) | 2018-07-05 |
| US20220214366A1 (en) | 2022-07-07 |
| US10753950B2 (en) | 2020-08-25 |
| US20210041464A1 (en) | 2021-02-11 |
| JP2013513802A (ja) | 2013-04-22 |
| WO2011072168A1 (en) | 2011-06-16 |
| WO2011072163A1 (en) | 2011-06-16 |
| US11549954B2 (en) | 2023-01-10 |
| CA2783797A1 (en) | 2011-06-16 |
| EP2510339A4 (en) | 2013-11-27 |
| US11852636B2 (en) | 2023-12-26 |
| US20240077503A1 (en) | 2024-03-07 |
| US20170115314A1 (en) | 2017-04-27 |
| US20180348236A1 (en) | 2018-12-06 |
| US20230146212A1 (en) | 2023-05-11 |
| JP2016026287A (ja) | 2016-02-12 |
| CN102753964A (zh) | 2012-10-24 |
| JP6113504B2 (ja) | 2017-04-12 |
| US20110240840A1 (en) | 2011-10-06 |
| JP6290145B2 (ja) | 2018-03-07 |
| US20120025067A1 (en) | 2012-02-02 |
| EP2510339A1 (en) | 2012-10-17 |
| US11280799B2 (en) | 2022-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12282032B2 (en) | Vitamin D metabolite determination utilizing mass spectrometry following derivatization | |
| US11808773B2 (en) | Mass spectrometry of steroidal compounds in multiplexed patient samples | |
| US11852636B2 (en) | Mass spectrometric determination of non-derivatized, non-metabolized vitamin D | |
| HK40035862A (en) | Mass spectrometry of steroidal compounds in multiplex samples |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150708 |